Dokumentdetails
ID

oai:pubmedcentral.nih.gov:8436...

Thema
Regular Issue Articles
Autor
Toffoli, Marco Higgins, Abigail Lee, Chiao Koletsi, Sofia Chen, Xiao Eberle, Michael Sedlazeck, Fritz J. Mullin, Stephen Proukakis, Christos Schapira, Anthony H.V.
Langue
en
Editor

John Wiley & Sons, Inc.

Kategorie

Wiley-Blackwell Online Open

Jahr

2021

Auflistungsdatum

01.12.2023

Schlüsselwörter
study parkinson age diagnosis cohort haplotypes disease
Metrisch

Zusammenfassung

BACKGROUND: GBA mutations are a common risk factor for Parkinson's disease (PD).

A recent study has suggested that GBA haplotypes, identified by intronic variants, can affect age at diagnosis of PD.

OBJECTIVES: In this study, we assess this hypothesis using long reads across a large cohort and the publicly available Accelerating Medicines Partnership–Parkinson's Disease (AMP‐PD) cohort.

METHODS: We recruited a PD cohort through the Remote Assessment of Parkinsonism Supporting Ongoing Development of Interventions in Gaucher Disease study (RAPSODI) and sequenced GBA using Oxford Nanopore technology.

Genetic and clinical data on the full AMP‐PD cohort were obtained from the online portal of the consortium.

RESULTS: A total of 1417 participants were analyzed.

There was no significant difference in age at PD diagnosis between the two main haplotypes of the GBA gene.

CONCLUSIONS: GBA haplotypes do not affect age at diagnosis of PD in the two independent cohorts studied.

© 2021 The Authors.

Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

Toffoli, Marco,Higgins, Abigail,Lee, Chiao,Koletsi, Sofia,Chen, Xiao,Eberle, Michael,Sedlazeck, Fritz J.,Mullin, Stephen,Proukakis, Christos,Schapira, Anthony H.V., 2021, Intronic Haplotypes in the GBA Gene Do Not Predict Age at Diagnosis of Parkinson's Disease, John Wiley & Sons, Inc.

Dokumentieren

Öffnen Öffnen

Teilen

Quelle

Artikel empfohlen von ES/IODE AI

MELAS: Phenotype Classification into Classic-versus-Atypical Presentations
presentations mitochondrial strokelike patients variability phenotype clinical melas
Protocol for the promoting resilience in stress management (PRISM) intervention: a multi-site randomized controlled trial for adolescents and young adults with advanced cancer
cancer quality of life anxiety depression hope coping skills communication intervention randomized ayas outcomes resilience care trial cancer prism-ac advanced